Allergy and immune therapy company ALK reports better sales than predicted for the second quarter of the year. The company has also saved some money on certain expenses and on postponing certain clinical activities, so now the Danish company is upgrading its revenue and earnings guidance for full-year 2021, according to a Monday press release.
Whereas the Danish company previously forecast growth in the range of 9-12 percent measured in local currency, now it predicts to grow between 10-12 percent. This optimism is particularly due to the company's tablet sales, which have gone better than expected. Now, the company estimates tablet sales will grow 25 percent or more, whereas it previously projected growth of around 25 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
Innovation Project Manager, Display Unit 
Production Director 
Senior QA Specialist 
Biomarker Operations Lead 
Scientific Writer 
Director Global Engineering 
Senior Project Manager (GMP - Life Science) 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Senior Chemical Safety Advisor 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
System Sales Development Consultant - Investment Projects, Merck Millipore 
SAP System Specialist (Product Supply) – Business Application Services 
Nordic Medical Affairs Manager 
Client Talent Acquisition Specialist 
(Senior) Drug Substance Specialist 
Communications Consultant 
Senior Manager, Clinical Trial Budget